Zoledronic Acid in Combination With Interleukin-2 to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allotransplant
NCT03862833
Hematopoietic Stem Cell Transplantation
Nantes, France
View Trial DetailsNCT Number: NCT02414113
Before considering high-GVHD Negative Outcome Score (GNOS) donor selection for routine clinical practice, this blinded prospective study will be carried out for assessment of severe GVHD (graft-versus-host-disease) reduction associated with selecting high-GNOS donors for allogeneic hematopoietic peripheral blood stem cell transplant. The objective of this prospective study is to show: (a) that GVHD reductions and donor availabilities as observed in the retrospective studies also apply to prospective samples that are collected and processed from on-going matched unrelated transplants, and (b) that high-GNOS donor selection readily fits into today's donor selection process, such as to facilitate access to the benefits of GVHD reduction. The prospective study is designed to be blinded, and will not involve specific donor selection nor any influence on clinical management or decision making by application of the GNOS technology.
To determine if some GNOS models perform better than others across different clinical centers, or across different recipient / donor attributes, 4 different specific GNOS models will be evaluated. Bootstrap computational analyses have been carried out on the retrospective data for the 4 GNOS models and will be tested and validated in this prospective study.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Observational
Washington University School of Medicine, St Louis, Missouri, United States
Enrollment of the recipient will occur prior to the unrelated donor search or haploidentical donor identification.
FOR UNRELATED DONORS:
When the unrelated donor search is formalized, the study team will submit a study participation request document to the NMDP for all potential donors that are being evaluated for an enrolled recipient. These documents will be relayed to the appropriate donor centers by the NMDP. This document informs the donor center that the potential donor's participation in this trial is being requested. The donor center then will approach the potential donor about participation in the trial. If the potential donor consents to participate, the required donor study samples will be obtained and shipped to the appropriate labs. This will conclude the potential donor's physical participation in the trial. The donor consent will be kept at the donor center and will not be provided to the investigator.
FOR HAPLOIDENTICAL DONORS:
Haploidentical donors will be identified by the transplant team caring for the recipient, and will follow the site's standard procedures for identification, HLA typing, and medical clearance for stem cell donation. Haploidentical donors will be approached by the transplant team or the study coordinator about participation in the trial. If the potential donor consents to participate, the required donor study samples will be obtained and shipped to the appropriate lab for processing prior to the start of growth factor for stem cell mobilization or prior to stem cell collection via bone marrow harvest.
FOR ALL DONORS:
At the time of HLA confirmatory typing, 24 mL of whole blood will be collected from donors.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Eligibility Criteria Prior to Unrelated Donor Search / Haploidentical Donor Identification:
Eligibility Criteria on Day 0:
Enrollment will occur prior to the unrelated donor search. Following donor selection, if the recipient does not meet the eligibility criteria listed for Day 0 or if the recipient does not proceed to stem cell transplantation within 12 months of enrollment, the donor/recipient pair will be non-evaluable for the study objectives. Non-evaluable donor/recipient pairs will be removed from trial and replaced.
Time frame: 100 days after HSCT
Time frame: 3 months
-Overall survival (OS) is defined as the date of transplant to the date of death from any cause.
Time frame: 100 days after HSCT
Time frame: 1 year
-A patient will be considered relapsed when there is a recurrence of the original malignant disease after transplantation
Washington University School of Medicine
Other
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03862833
Hematopoietic Stem Cell Transplantation
Nantes, France
View Trial DetailsNCT06198517
Cystitis, Cystitis, Hemorrhagic
Zhengzhou, Henan, China
View Trial DetailsNCT06904053
Hematopoietic Stem Cell Transplantation
Bethesda, Maryland, United States
View Trial DetailsNCT04635397
Hematopoietic Stem Cell Transplantation
Nice, CHU de NICE, France
View Trial Details